$BCAB
BioAtla, Inc.

2022 Q3 Form 10-Q Financial Statement

#000095017022022036 Filed on November 04, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2021 Q3
Revenue $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.340M $7.142M
YoY Change -11.23% 54.42%
% of Gross Profit
Research & Development $19.84M $16.55M
YoY Change 19.85% 240.32%
% of Gross Profit
Depreciation & Amortization $300.0K $380.0K
YoY Change -21.05% 31.49%
% of Gross Profit
Operating Expenses $26.18M $23.70M
YoY Change 10.48% 190.2%
Operating Profit -$26.18M -$23.70M
YoY Change 10.48% 195.63%
Interest Expense $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $400.0K $765.0K
YoY Change -47.71% -121.15%
Pretax Income -$25.78M -$22.93M
YoY Change 12.42% 17.84%
Income Tax
% Of Pretax Income
Net Earnings -$25.78M -$22.93M
YoY Change 12.42% 97.13%
Net Earnings / Revenue
Basic Earnings Per Share -$0.69 -$0.68
Diluted Earnings Per Share -$0.69 -$676.2K
COMMON SHARES
Basic Shares Outstanding 37.52M 32.32M
Diluted Shares Outstanding 37.52M 33.91M

Balance Sheet

Concept 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $178.1M $269.9M
YoY Change -34.01% 375.22%
Cash & Equivalents $178.1M $269.9M
Short-Term Investments
Other Short-Term Assets $5.189M $3.592M
YoY Change 44.46% 349.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $183.3M $273.5M
YoY Change -32.98% 375.68%
LONG-TERM ASSETS
Property, Plant & Equipment $3.002M $3.908M
YoY Change -23.18% -2.3%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $154.0K $154.0K
YoY Change 0.0% -88.15%
Total Long-Term Assets $5.803M $4.062M
YoY Change 42.86% -23.36%
TOTAL ASSETS
Total Short-Term Assets $183.3M $273.5M
Total Long-Term Assets $5.803M $4.062M
Total Assets $189.1M $277.6M
YoY Change -31.87% 342.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.696M $1.550M
YoY Change 138.45% -64.77%
Accrued Expenses $4.477M $3.008M
YoY Change 48.84% 67.11%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $23.83M $45.23M
YoY Change -47.32% 26.33%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $22.65M $1.699M
YoY Change 1233.31% -19.1%
Total Long-Term Liabilities $22.65M $1.699M
YoY Change 1233.31% -39.32%
TOTAL LIABILITIES
Total Short-Term Liabilities $23.83M $45.23M
Total Long-Term Liabilities $22.65M $1.699M
Total Liabilities $46.48M $46.93M
YoY Change -0.95% 21.89%
SHAREHOLDERS EQUITY
Retained Earnings -$265.3M -$162.9M
YoY Change 62.86%
Common Stock $4.000K $4.000K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $142.6M $230.7M
YoY Change
Total Liabilities & Shareholders Equity $189.1M $277.6M
YoY Change -31.87% 342.0%

Cashflow Statement

Concept 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$25.78M -$22.93M
YoY Change 12.42% 97.13%
Depreciation, Depletion And Amortization $300.0K $380.0K
YoY Change -21.05% 31.49%
Cash From Operating Activities -$24.02M -$12.73M
YoY Change 88.72% -17.71%
INVESTING ACTIVITIES
Capital Expenditures -$58.00K -$99.00K
YoY Change -41.41% -13.16%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$58.00K -$99.00K
YoY Change -41.41% -13.16%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -96.00K 75.14M
YoY Change -100.13% 4.15%
NET CHANGE
Cash From Operating Activities -24.02M -12.73M
Cash From Investing Activities -58.00K -99.00K
Cash From Financing Activities -96.00K 75.14M
Net Change In Cash -24.17M 62.32M
YoY Change -138.79% 10.16%
FREE CASH FLOW
Cash From Operating Activities -$24.02M -$12.73M
Capital Expenditures -$58.00K -$99.00K
Free Cash Flow -$23.96M -$12.63M
YoY Change 89.74% -17.74%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
bcab Collaboration Agreement Start Date
CollaborationAgreementStartDate
2019-12
bcab Payments For Taxes Related To Net Settlement Of Equity Awards1
PaymentsForTaxesRelatedToNetSettlementOfEquityAwards1
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Proceeds From Sale Of Other Property Plant And Equipment
ProceedsFromSaleOfOtherPropertyPlantAndEquipment
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
bcab Company Formation Date
CompanyFormationDate
2007-03
us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
CY2021Q3 us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
dei Amendment Flag
AmendmentFlag
false
us-gaap Interest Expense
InterestExpense
us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
CY2021Q3 us-gaap Interest Expense
InterestExpense
bcab Tax Related To Net Settlement Of Equity Awards Included In Accounts Payable And Accrued Expenses
TaxRelatedToNetSettlementOfEquityAwardsIncludedInAccountsPayableAndAccruedExpenses
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
bcab Equity Issuance Costs Included In Accounts Payable And Accrued Expenses
EquityIssuanceCostsIncludedInAccountsPayableAndAccruedExpenses
dei Entity Central Index Key
EntityCentralIndexKey
0001826892
CY2022Q3 us-gaap Interest Expense
InterestExpense
CY2022Q3 us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39787
dei Entity Registrant Name
EntityRegistrantName
BIOATLA, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1922320
dei Entity Address Address Line1
EntityAddressAddressLine1
11085 Torreyana Road
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
558-0708
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
BCAB
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
178120000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
244979000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5189000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2313000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
183309000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
247292000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3002000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3676000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2647000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3300000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
154000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
154000
CY2022Q3 us-gaap Assets
Assets
189112000
CY2021Q4 us-gaap Assets
Assets
254422000
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
22327000
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
18424000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1498000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1389000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
23825000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
19813000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2847000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3982000
CY2022Q3 bcab Liability To Licensor
LiabilityToLicensor
19806000
CY2021Q4 bcab Liability To Licensor
LiabilityToLicensor
19806000
CY2022Q3 us-gaap Liabilities
Liabilities
46478000
CY2021Q4 us-gaap Liabilities
Liabilities
43601000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
200000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
200000000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36365317
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36365317
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35799233
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35799233
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
4000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
407888000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
397136000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-265258000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-186319000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
142634000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
210821000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
189112000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
254422000
us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
250000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19839000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16553000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
57473000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
41826000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6340000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7142000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22107000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
31376000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
26179000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
23695000
us-gaap Operating Expenses
OperatingExpenses
79580000
us-gaap Operating Expenses
OperatingExpenses
73202000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-26179000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-23695000
us-gaap Operating Income Loss
OperatingIncomeLoss
-79580000
us-gaap Operating Income Loss
OperatingIncomeLoss
-72952000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
370000
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
76000
us-gaap Investment Income Interest
InvestmentIncomeInterest
601000
us-gaap Investment Income Interest
InvestmentIncomeInterest
254000
us-gaap Interest Expense
InterestExpense
3000
CY2021Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
690000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
690000
CY2022Q3 bcab Other Income Expense
OtherIncomeExpense
30000
CY2021Q3 bcab Other Income Expense
OtherIncomeExpense
-1000
bcab Other Income Expense
OtherIncomeExpense
40000
bcab Other Income Expense
OtherIncomeExpense
-1000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
400000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
765000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
641000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
940000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-25779000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-22930000
us-gaap Net Income Loss
NetIncomeLoss
-78939000
us-gaap Net Income Loss
NetIncomeLoss
-72012000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.69
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.69
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.68
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.68
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.11
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.11
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.13
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37516769
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37516769
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33909460
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33909460
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37420531
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37420531
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33751558
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33751558
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
164952000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3588000
CY2022Q3 bcab Taxes Related To Net Share Settlement Of Equity Awards
TaxesRelatedToNetShareSettlementOfEquityAwards
-127000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-25779000
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
142634000
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
178023000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4366000
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
71054000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
140000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-22930000
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
230653000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
210821000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11062000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
19000
bcab Taxes Related To Net Share Settlement Of Equity Awards
TaxesRelatedToNetShareSettlementOfEquityAwards
-329000
us-gaap Net Income Loss
NetIncomeLoss
-78939000
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
142634000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
209974000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
21307000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
71054000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
140000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
190000
us-gaap Net Income Loss
NetIncomeLoss
-72012000
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
230653000
us-gaap Net Income Loss
NetIncomeLoss
-78939000
us-gaap Net Income Loss
NetIncomeLoss
-72012000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
901000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1016000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-6000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-4000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
690000
us-gaap Share Based Compensation
ShareBasedCompensation
11062000
us-gaap Share Based Compensation
ShareBasedCompensation
21307000
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-3000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2876000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1516000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
4146000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
10844000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-373000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-221000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-66073000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-41265000
us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
237000
us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
835000
us-gaap Proceeds From Sale Of Other Property Plant And Equipment
ProceedsFromSaleOfOtherPropertyPlantAndEquipment
3000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-234000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-835000
us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
1911000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
75001000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
140000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
19000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
190000
bcab Payments For Taxes Related To Net Settlement Of Equity Awards1
PaymentsForTaxesRelatedToNetSettlementOfEquityAwards1
571000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-552000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
73420000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-66859000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
31320000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
244979000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
238605000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
178120000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
269925000
us-gaap Property Plant And Equipment Additions
PropertyPlantAndEquipmentAdditions
1000
us-gaap Property Plant And Equipment Additions
PropertyPlantAndEquipmentAdditions
8000
bcab Equity Issuance Costs Included In Accounts Payable And Accrued Expenses
EquityIssuanceCostsIncludedInAccountsPayableAndAccruedExpenses
3947000
bcab Tax Related To Net Settlement Of Equity Awards Included In Accounts Payable And Accrued Expenses
TaxRelatedToNetSettlementOfEquityAwardsIncludedInAccountsPayableAndAccruedExpenses
49000
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-265300000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5189000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2313000
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8144000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7933000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">preparation of the Company’s condensed consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s condensed consolidated financial statements and accompanying notes. The most significant estimates in the Company’s condensed consolidated financial statements relate to revenue recognition, accruals for research and development costs, and equity-based compensation. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of revenue and expenses that are not readily apparent from other sources. Actual</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">results </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.</span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentrations of Risk</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to a significant concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentrations of Risk</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to a significant concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</span></p>
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8144000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7933000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3274981
CY2022Q3 bcab Prepaid Research And Development Expense
PrepaidResearchAndDevelopmentExpense
3978000
CY2021Q4 bcab Prepaid Research And Development Expense
PrepaidResearchAndDevelopmentExpense
1811000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
0
CY2022Q3 bcab Other Prepaid Expenses And Current Assets
OtherPrepaidExpensesAndCurrentAssets
519000
CY2021Q4 bcab Other Prepaid Expenses And Current Assets
OtherPrepaidExpensesAndCurrentAssets
502000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3463720
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3274981
CY2022Q3 bcab Prepaid Research And Development Expense
PrepaidResearchAndDevelopmentExpense
3978000
CY2021Q4 bcab Prepaid Research And Development Expense
PrepaidResearchAndDevelopmentExpense
1811000
CY2022Q3 us-gaap Prepaid Insurance
PrepaidInsurance
692000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
0
CY2022Q3 bcab Other Prepaid Expenses And Current Assets
OtherPrepaidExpensesAndCurrentAssets
519000
CY2021Q4 bcab Other Prepaid Expenses And Current Assets
OtherPrepaidExpensesAndCurrentAssets
502000
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5142000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4257000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3002000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3676000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3696000
CY2021Q4 bcab Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
13501000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
939000
CY2022Q3 us-gaap Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
0
CY2021Q4 us-gaap Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
0
CY2022Q3 us-gaap Derivative Asset Fair Value Gross Liability
DerivativeAssetFairValueGrossLiability
0
CY2021Q4 us-gaap Derivative Asset Fair Value Gross Liability
DerivativeAssetFairValueGrossLiability
0
us-gaap Debt Conversion Description
DebtConversionDescription
The Company did not have any outstanding debt as of September 30, 2022 or December 31, 2021. In April 2020, the Company borrowed $0.7 million under the Paycheck Protection Program (“PPP”) under the CARES Act. The loan was subsequently forgiven in July 2021. The $0.7 million balance of the forgiven loan was recognized as other income on the Company's Statement of Operations for the three and nine months ended September 30, 2021. For the three and nine months ended September 30, 2021, the Company recognized interest expense related to its outstanding debt of $0 and $3,000, respectively.
us-gaap Lessor Operating Lease Option To Extend
LessorOperatingLeaseOptionToExtend
The lease expires in July 2025 and the Company has an option to extend the term of the lease for an additional five years. Additionally, the lease includes certain rent abatement, rent escalations, tenant improvement allowances and additional charges for common area maintenance and other costs.
bcab Lessor Operating Leases Option To Extend
LessorOperatingLeasesOptionToExtend
P5Y
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5142000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4257000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3002000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3676000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3696000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1179000
CY2022Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
2979000
CY2021Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
2671000
CY2022Q3 bcab Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
14713000
CY2021Q4 bcab Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
13501000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
939000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1073000
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
22327000
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
18424000
CY2022Q3 us-gaap Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
0
CY2021Q4 us-gaap Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
0
CY2022Q3 us-gaap Derivative Asset Fair Value Gross Liability
DerivativeAssetFairValueGrossLiability
0
CY2021Q4 us-gaap Derivative Asset Fair Value Gross Liability
DerivativeAssetFairValueGrossLiability
0
us-gaap Debt Conversion Description
DebtConversionDescription
The Company did not have any outstanding debt as of September 30, 2022 or December 31, 2021. In April 2020, the Company borrowed $0.7 million under the Paycheck Protection Program (“PPP”) under the CARES Act. The loan was subsequently forgiven in July 2021. The $0.7 million balance of the forgiven loan was recognized as other income on the Company's Statement of Operations for the three and nine months ended September 30, 2021. For the three and nine months ended September 30, 2021, the Company recognized interest expense related to its outstanding debt of $0 and $3,000, respectively.
us-gaap Lessor Operating Lease Option To Extend
LessorOperatingLeaseOptionToExtend
The lease expires in July 2025 and the Company has an option to extend the term of the lease for an additional five years. Additionally, the lease includes certain rent abatement, rent escalations, tenant improvement allowances and additional charges for common area maintenance and other costs.
bcab Lessor Operating Leases Option To Extend
LessorOperatingLeasesOptionToExtend
P5Y
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
261000
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
261000
us-gaap Operating Lease Cost
OperatingLeaseCost
782000
us-gaap Variable Lease Cost
VariableLeaseCost
384000
us-gaap Lease Cost
LeaseCost
1166000
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y9M
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0350
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0350
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
401000
us-gaap Operating Lease Payments
OperatingLeasePayments
1003000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
261000
us-gaap Operating Lease Cost
OperatingLeaseCost
782000
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
132000
CY2021Q3 us-gaap Variable Lease Cost
VariableLeaseCost
128000
us-gaap Variable Lease Cost
VariableLeaseCost
328000
us-gaap Variable Lease Cost
VariableLeaseCost
384000
CY2022Q3 us-gaap Lease Cost
LeaseCost
393000
CY2021Q3 us-gaap Lease Cost
LeaseCost
389000
us-gaap Lease Cost
LeaseCost
1110000
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y9M
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y9M
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
401000
CY2021Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
370000
us-gaap Operating Lease Payments
OperatingLeasePayments
1155000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
845000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
0
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
4567000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
401000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1636000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1685000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
845000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
4567000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
222000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
4345000
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
3588000
CY2021Q3 us-gaap Share Based Compensation
ShareBasedCompensation
4366000
us-gaap Share Based Compensation
ShareBasedCompensation
11062000
us-gaap Share Based Compensation
ShareBasedCompensation
21307000
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
3588000
CY2021Q3 us-gaap Share Based Compensation
ShareBasedCompensation
4366000
us-gaap Share Based Compensation
ShareBasedCompensation
11062000
us-gaap Share Based Compensation
ShareBasedCompensation
21307000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
5400000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
5400000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.748
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0099
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y14D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M9D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent
SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
0.15
CY2021 bcab Warrants Expired And Unexercised
WarrantsExpiredAndUnexercised
566586
CY2022Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7578950
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
6247701
us-gaap Revenues
Revenues
300000
CY2022Q3 us-gaap Revenues
Revenues
0
us-gaap Revenues
Revenues
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.748
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.747
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0209
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0099
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y14D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M9D
CY2022Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7578950
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
6247701
CY2022Q3 us-gaap Revenues
Revenues
0
us-gaap Revenues
Revenues
0
us-gaap Related Party Transaction Terms And Manner Of Settlement
RelatedPartyTransactionTermsAndMannerOfSettlement
(i) a lump sum payment equal to 18 months of Ms. Anderson Short’s then-current base salary, (ii) a payment at her targeted bonus rate for 2021, pro-rated to the date of her termination of employment, and (iii) full accelerated vesting of her equity awards including 7,747 stock options and 138,461 restricted stock units. The modification of these equity awards resulted in an incremental fair value of $7.0 million which was recognized on a straight-line basis over the transition service period which ended on the separation date. For the three and nine months ended September 30, 2021, the Company recognized $0 and $1.0 million, respectively, related to the lump sum salary payment and target bonus. The Company also recognized non-cash stock-based compensation charges of $0 and $9.4 million related to the modified equity awards for the three and nine months ended September 30, 2021, respectively. No unrecognized stock-based compensation remained as of September 30, 2021.
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
0
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
0
CY2021 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
0

Files In Submission

Name View Source Status
0000950170-22-022036-index-headers.html Edgar Link pending
0000950170-22-022036-index.html Edgar Link pending
0000950170-22-022036.txt Edgar Link pending
0000950170-22-022036-xbrl.zip Edgar Link pending
bcab-20220930.htm Edgar Link pending
bcab-20220930.xsd Edgar Link pending
bcab-ex10_2.htm Edgar Link pending
bcab-ex31_1.htm Edgar Link pending
bcab-ex31_2.htm Edgar Link pending
bcab-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
bcab-20220930_def.xml Edgar Link unprocessable
bcab-20220930_lab.xml Edgar Link unprocessable
bcab-20220930_pre.xml Edgar Link unprocessable
bcab-20220930_htm.xml Edgar Link completed
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
bcab-20220930_cal.xml Edgar Link unprocessable